Acute bronchitis - observational study with EPs® 7630 has been started
2024-12-13
As a research-based company, we are committed to continually expanding the evidence base for our products. A key area of focus is the utilization of the medicinal products in a real-world setting. EPs® 7630 is an extract derived from the roots of the Cape geranium (Pelargonium sidoides). Medicinal products containing this active ingredient have been approved for the treatment of respiratory tract infections, including acute bronchitis, in numerous countries across Asia, Europe, Australia and Central and South America.
We have started a prospective observational study with EPs® 7630 at the beginning of the current cold season in Switzerland. The objective is to include approximately 400 patients diagnosed with acute bronchitis. The aim is to have a positive virus test at the start of treatment for at least 216 patients. We are investigating the association between the start of treatment with EPs® 7630 and the reduction of viral shedding, as well as the course of symptoms of bronchitis. Further information on the study is available at the following link: RAPS - registry.
We aim to present the results in the second half of 2025.